File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects of long-term rofecoxib on gastric intestinal metaplasia: Results of a randomized controlled trial

TitleEffects of long-term rofecoxib on gastric intestinal metaplasia: Results of a randomized controlled trial
Authors
Issue Date2006
PublisherAmerican Association for Cancer Research
Citation
Clinical Cancer Research, 2006, v. 12 n. 15, p. 4766-4772 How to Cite?
AbstractPurpose: Gastric cancer and its premalignant gastric lesion, intestinal metaplasia (IM), frequently express cyclooxygenase-2 (COX-2) at high levels. We tested whether long-term use of specific COX-2 inhibitors regress gastric IM. Experimental Design: This is a double-blind, randomized, placebo-controlled trial. Individuals with confirmed IM and Helicobacter pylori clearance were randomized to receive rofecoxib 25 mg daily or placebo. Endoscopy was done at baseline, at the end of year 1, and at the end of year 2, with multiple biopsies taken from the antrum and corpus. The primary end point was the proportion of subjects with regression of IM. Secondary end points were the severity of other histologic variables and the proportion of subjects with complete regression of IM. Results: Two-hundred and thirteen subjects with confirmed IM were randomized. The proportion of subjects with the regression of IM did not differ significantly between rofecoxib and placebo groups (antrum, 24.5% versus 26.9%; P = 0.74; corpus, 4.3% versus 2.2%; P = 0.68). Patients on rofecoxib (19.1%) and on placebo (16.1%) had no IM detected in the stomach (P = 0.59). There was also no significant difference in the severity of IM between the two treatment groups (P ≥ 0.3). Conclusions: There was no trend to suggest that treatment with rofecoxib for 2 years resulted in the regression of gastric IM. Although our findings cast doubt on the reversibility of gastric IM by COX-2 inhibitor, further studies are needed to establish the role of COX-2 inhibitors in different stages of gastric carcinogenesis. © 2006 American Association for Cancer Research.
Persistent Identifierhttp://hdl.handle.net/10722/132854
ISSN
2015 Impact Factor: 8.738
2015 SCImago Journal Rankings: 5.314
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, WKen_HK
dc.contributor.authorNg, EKWen_HK
dc.contributor.authorChan, FKLen_HK
dc.contributor.authorChan, WYen_HK
dc.contributor.authorChan, KFen_HK
dc.contributor.authorAuyeung, ACMen_HK
dc.contributor.authorLam, CCHen_HK
dc.contributor.authorLau, JYWen_HK
dc.contributor.authorSung, JJYen_HK
dc.date.accessioned2011-04-04T07:57:27Z-
dc.date.available2011-04-04T07:57:27Z-
dc.date.issued2006en_HK
dc.identifier.citationClinical Cancer Research, 2006, v. 12 n. 15, p. 4766-4772en_HK
dc.identifier.issn1078-0432en_HK
dc.identifier.urihttp://hdl.handle.net/10722/132854-
dc.description.abstractPurpose: Gastric cancer and its premalignant gastric lesion, intestinal metaplasia (IM), frequently express cyclooxygenase-2 (COX-2) at high levels. We tested whether long-term use of specific COX-2 inhibitors regress gastric IM. Experimental Design: This is a double-blind, randomized, placebo-controlled trial. Individuals with confirmed IM and Helicobacter pylori clearance were randomized to receive rofecoxib 25 mg daily or placebo. Endoscopy was done at baseline, at the end of year 1, and at the end of year 2, with multiple biopsies taken from the antrum and corpus. The primary end point was the proportion of subjects with regression of IM. Secondary end points were the severity of other histologic variables and the proportion of subjects with complete regression of IM. Results: Two-hundred and thirteen subjects with confirmed IM were randomized. The proportion of subjects with the regression of IM did not differ significantly between rofecoxib and placebo groups (antrum, 24.5% versus 26.9%; P = 0.74; corpus, 4.3% versus 2.2%; P = 0.68). Patients on rofecoxib (19.1%) and on placebo (16.1%) had no IM detected in the stomach (P = 0.59). There was also no significant difference in the severity of IM between the two treatment groups (P ≥ 0.3). Conclusions: There was no trend to suggest that treatment with rofecoxib for 2 years resulted in the regression of gastric IM. Although our findings cast doubt on the reversibility of gastric IM by COX-2 inhibitor, further studies are needed to establish the role of COX-2 inhibitors in different stages of gastric carcinogenesis. © 2006 American Association for Cancer Research.en_HK
dc.languageengen_US
dc.publisherAmerican Association for Cancer Researchen_US
dc.relation.ispartofClinical Cancer Researchen_HK
dc.subject.meshAdenocarcinoma - drug therapy - pathologyen_HK
dc.subject.meshAntineoplastic Agents - administration & dosageen_HK
dc.subject.meshDouble-Blind Methoden_HK
dc.subject.meshDrug Administration Scheduleen_HK
dc.subject.meshFollow-Up Studiesen_HK
dc.subject.meshGastrointestinal Neoplasms - drug therapy - pathologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLactones - administration & dosageen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMetaplasia - drug therapy - pathologyen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshNeoplasm Stagingen_HK
dc.subject.meshPlacebosen_HK
dc.subject.meshProspective Studiesen_HK
dc.subject.meshSulfones - administration & dosageen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleEffects of long-term rofecoxib on gastric intestinal metaplasia: Results of a randomized controlled trialen_HK
dc.typeArticleen_HK
dc.identifier.emailLeung, WK:waikleung@hku.hken_HK
dc.identifier.authorityLeung, WK=rp01479en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1158/1078-0432.CCR-06-0693en_HK
dc.identifier.pmid16899628-
dc.identifier.scopuseid_2-s2.0-33748069473en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33748069473&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume12en_HK
dc.identifier.issue15en_HK
dc.identifier.spage4766en_HK
dc.identifier.epage4772en_HK
dc.identifier.isiWOS:000239750400041-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLeung, WK=7201504523en_HK
dc.identifier.scopusauthoridNg, EKW=24328695100en_HK
dc.identifier.scopusauthoridChan, FKL=7202586434en_HK
dc.identifier.scopusauthoridChan, WY=37041920900en_HK
dc.identifier.scopusauthoridChan, KF=14324453900en_HK
dc.identifier.scopusauthoridAuyeung, ACM=12760347200en_HK
dc.identifier.scopusauthoridLam, CCH=14321941100en_HK
dc.identifier.scopusauthoridLau, JYW=13907867100en_HK
dc.identifier.scopusauthoridSung, JJY=35405352400en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats